Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism

Cinacalcet HCl (AMG 073) is an investigational oral calcimimetic drug currently being evaluated for the treatment of primary and secondary hyperparathyroidism (HPT). Calcimimetics bind to the calcium-sensing receptors of the parathyroid glands and lower the sensitivity for receptor activation by extracellular calcium, thereby diminishing parathyroid hormone release. Cinacalcet HCl has demonstrated efficacy in controlling the hypercalcaemia of severe primary HPT and in reducing parathyroid hormone levels in patients with secondary HPT. Asymptomatic dose-dependent hypocalcaemia has occurred in some clinical trials. This drug has a favourable pharmacokinetic profile compared to its precursors and will prove useful as an additional/alternative agent in patients with primary and secondary HPT.

[1]  S. Rosansky,et al.  The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. , 2003, Journal of the American Society of Nephrology : JASN.

[2]  S. Moe,et al.  The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. , 2003, Kidney international.

[3]  G. Eknoyan,et al.  Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  J. Rastad,et al.  Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. , 2002, The Journal of clinical endocrinology and metabolism.

[5]  C. Marcocci,et al.  Epidemiology of primary hyperparathyroidism in Europe. , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  F. Recio,et al.  Persistent downregulation of calcium-sensing receptor mRNA in rat parathyroids when severe secondary hyperparathyroidism is reversed by an isogenic kidney transplantation. , 2002, Journal of the American Society of Nephrology : JASN.

[7]  N. Koszewski,et al.  Update on vitamin D and its newer analogues: actions and rationale for treatment in chronic renal failure. , 2002, Kidney international.

[8]  J. Coburn,et al.  The calcimimetic agents: perspectives for treatment. , 2002, Kidney international. Supplement.

[9]  K. Eckardt,et al.  Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  R. Poveda,et al.  Goodpasture syndrome during the course of a Schönlein-Henoch purpura. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  F. Locatelli,et al.  Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[12]  W. Goodman,et al.  The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. , 2002, Journal of the American Society of Nephrology : JASN.

[13]  W. Goodman.  Calcimimetic agents and secondary hyperparathyroidism: treatment and prevention. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  G. Wolf,et al.  Leptin and renal disease. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[15]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  S. Ganesh,et al.  Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. , 2001, Journal of the American Society of Nephrology : JASN.

[17]  K. O̸lgaard,et al.  Prevention of uremic bone disease using calcimimetic compounds. , 2001, Annual review of medicine.

[18]  W. Liu,et al.  A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. , 2000, Kidney international.

[19]  S. Miller,et al.  Activation of the calcium receptor by a calcimimetic compound halts the progression of secondary hyperparathyroidism in uremic rats. , 2000, Journal of the American Society of Nephrology : JASN.

[20]  N. Nagano,et al.  Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. , 2000, Bone.

[21]  N. Nagano,et al.  Calcimimetic NPS R-568 prevents parathyroid hyperplasia in rats with severe secondary hyperparathyroidism. , 2000, Kidney international.

[22]  F. Llach,et al.  Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences. , 1999, Kidney international. Supplement.

[23]  A. Dusso,et al.  The role of phosphorus in the development of secondary hyperparathyroidism and parathyroid cell proliferation in chronic renal failure. , 1999, The American journal of the medical sciences.

[24]  J. Garrett,et al.  Allosteric activation of the Ca2+ receptor expressed in Xenopus laevis oocytes by NPS 467 or NPS 568. , 1998, Molecular pharmacology.

[25]  F. Port,et al.  Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[26]  S. Silverberg,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Treatment of Hypercalcemia Secondary to Parathyroid Carcinoma with a Novel Calcimimetic Agent , 1997 .

[27]  N. Nagano,et al.  NPS R-568 halts or reverses osteitis fibrosa in uremic rats. , 1998, Kidney international.

[28]  N. Nagano,et al.  The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. , 1997, The Journal of clinical investigation.

[29]  H. W. Harris,et al.  Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. , 1997, The Journal of clinical investigation.

[30]  E. Brown,et al.  Localization of the extracellular Ca(2+)-sensing receptor and PTH/PTHrP receptor in rat kidney. , 1996, The American journal of physiology.

[31]  J. Delmez,et al.  Pathogenesis of secondary hyperparathyroidism. , 1999, Kidney international. Supplement.

[32]  E. Brown,et al.  Molecular mechanisms underlying the sensing of extracellular Ca2+ by parathyroid and kidney cells. , 1995, European Journal of Endocrinology.

[33]  J. Seidman,et al.  Mutations in the human Ca2+-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism , 1993, Cell.

[34]  M. Hediger,et al.  Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid , 1993, Nature.

[35]  L. Melton,et al.  Epidemiology of primary hyperparathyroidism , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.